TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21666156
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Study: 21666156
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of Edmonston-Zagreb measles vaccine (MV) at 6 and 9 months
Study: 21666156
Drug: Control group:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group: Measles vaccine at 9 months only (for HIV-uninfected children)
Study: 21666156
Drug: HIV-infected children
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-infected children receiving measles vaccine
Study: 19626051
Drug: Alemtuzumab monotherapy
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab monotherapy as first-line therapy
Study: 19626051
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of alemtuzumab
Study: 19626051
Drug: Alemtuzumab combination
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Alemtuzumab combination therapy and consolidation therapy
Study: 14695461
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (n=89)
Study: 11236832
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg alcohol with reinforcement (money and verbal approval)
Study: 11236832
Drug: 0.56 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.56 g/kg alcohol without reinforcement
Study: 9310521
Drug: Dexamphetamine (DEX)
Normalized name: Dexamphetamine
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamphetamine (DEX) 0.15 mg/kg/dose
Study: 9310521
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.3 mg/kg/dose
Study: 3805657
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg nightly)
Study: 3805657
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g/day)
Study: 23130649
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg GMZ2 vaccine in pre-school children
Study: 23130649
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine in vaccinated adults
Study: 17021884
Drug: Dolasetron 1
Normalized name: dolasetron 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron 1 mg/kg body weight during surgery
Study: 7737712
Drug: Fosinopril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (10 to 20 mg)
Study: 2390186
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution (OS) containing the concentrated official formula in packets (group A)
Study: 31109126
Drug: Cascade Ensemble
Normalized name: CASCADE
DrugBank: Flufenoxuron (DB15006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cascade Ensemble Learning (CELearning) model using XGBoost, Random Forest, ExtraTrees, and Softmax Regression; details on dosage and duration not applicable as this is a computational model.
Study: 27807887
Drug: Resveratrol 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 480 mg/day for 4 weeks
Study: 21098476
Drug: 1-dose group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-dose group (500 mg oral dose 2 hours before procedure)
Study: 21098476
Drug: 2-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose group (500 mg oral dose 2 hours before procedure and an additional dose 8 hours later)
Study: 21098476
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (1-dose and 2-dose)
Study: 11935164
Drug: Intracameral injections
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral injections of corticosteroids
Study: 7575694
Drug: Hydroxychloroquine 400
Normalized name: hydroxychloroquine 400 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 400 mg/day plus Piroxicam 20 mg/day
Study: 2403063
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms vitamin D daily for 6 weeks
Study: 7013586
Drug: Levamisole as
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole as an adjunct to routine chemotherapy
Study: 7013586
Drug: Routine chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapy for tuberculosis only (Control)
Study: 24136368
Drug: Oral glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycerol
Study: 24136368
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (glycerol and acetaminophen)
Study: 23304075
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 10 mL of 0.5% bupivacaine
Study: 23304075
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 10 mL of 0.5% bupivacaine on one side and 10 mL of normal saline (NSS) placebo on the opposite side
Study: 23304075
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: 10 mL of NSS placebo per side
Study: 20438534
Drug: Heparin‐induced LDL‐precipitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐induced LDL‐precipitation (HELP)
Study: 18356633
Drug: Conventional amikacin
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Conventional amikacin dosing
Study: 16544143
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2 and cisplatin 75 mg/m2
Study: 16544143
Drug: docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel 75 mg/m2, cisplatin 75 mg/m2, and 5‐FU 750 mg/m2/day
Study: 8911706
Drug: Levocabastine eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocabastine eye drops (0.5 mg/mL)
Study: 1918421
Drug: Venlafaxine 25
Normalized name: venlafaxine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 25 mg three times a day
Study: 1918421
Drug: Venlafaxine 75
Normalized name: venlafaxine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 75 mg three times a day
Study: 1918421
Drug: Venlafaxine 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 125 mg three times a day
Study: 7143458
Drug: Therapy focused
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy focused on obtaining orgasm through self‐stimulation
Study: 21326120
Drug: Auricular acupressure
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular acupressure therapy for 4 weeks
Study: 18061058
Drug: Total cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total cholesterol (1 mmol/L lower)
Study: 9585795
Drug: Ritonavir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (300 mg on day 15, 400 mg on day 16, and 500 mg on days 17 to 24)
Study: 9585795
Drug: Rifabutin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifabutin (150 mg daily for 24 days) with placebo
Study: 3127076
Drug: Intravenous NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NTG combined with intravenous NAC (5 g 6 hourly)
Study: 3127076
Drug: Intravenous NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NTG alone
Study: 3127076
Drug: Intravenous NTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous NTG and continuously infused NAC (10 g/day)
Study: 26121725
Drug: Oral sucrose
Normalized name: TootSweet 24% Oral Sucrose Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral sucrose prior to echocardiography
Study: 26121725
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral sucrose)
Study: 16766440
Drug: Hypnotic suggestion
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic suggestion for blindness with increased brightness of the light during suggestion in Study 1
Study: 22995323
Drug: SB‐656933 50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐656933 50mg once daily for 28 days
Study: 22995323
Drug: SB‐656933 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB‐656933 20mg once daily for 28 days
Study: 19106506
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy with S‐1 and cisplatin (IP group)
Study: 19106506
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy with S‐1 and cisplatin (IV group)
Study: 16624457
Drug: Encepur (comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encepur (comparator vaccine, first vaccination)
Study: 16624457
Drug: Encepur (comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encepur (comparator vaccine, second vaccination)
Study: 16624457
Drug: Encepur (comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encepur (comparator vaccine, third vaccination)
Study: 8068472
Drug: Captopril 100
Normalized name: captopril 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 100 mg/day
Study: 29452685
Drug: Bilateral subthalamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral subthalamic stimulation plus medical therapy
Study: 27943563
Drug: DCV-TRIO (daclatasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 4 weeks
Study: 27943563
Drug: DCV-TRIO (daclatasvir
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCV-TRIO (daclatasvir 30 mg, asunaprevir 200 mg, beclabuvir 75 mg) twice-daily + sofosbuvir 400 mg once-daily for 6 weeks
Study: 27943563
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline HCV-RNA <2 million IU/mL
Study: 27943563
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with baseline HCV-RNA ≥2 million IU/mL
Study: 21174610
Drug: Tailored and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored and dose-dense EC followed by docetaxel (arm A)
Study: 21174610
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose EC followed by docetaxel (arm B)
Study: 18339132
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) 2 g/d
Study: 18339132
Drug: Sirolimus (SRL)
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus (SRL) loading dose of 15 mg, 5 mg/d till day 7 and 2 mg/d thereafter
Study: 16542443
Drug: Solution-focused follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused follow-up (n = 53)
Study: 27017450
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (n = 50)
Study: 12685885
Drug: Inhaled zanamivir
Normalized name: zanamivir Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled zanamivir 10 mg via Diskhaler twice daily for 5 days
Study: 11105734
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily, titrated to a maximum of 200 mg daily)
Study: 9365042
Drug: Serum anti‐p53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti‐p53 antibody positivity
Study: 9365042
Drug: p53 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: p53 antibody
Study: 9365042
Drug: Bilirubin and
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilirubin and p53 antibody
Study: 1556197
Drug: Sensory Integration
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sensory Integration Therapy (SI)
Study: 30955980
Drug: 1 booster
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 booster dose of 45 mcg of IIV1 A/H7N9 hemagglutinin
Study: 19892414
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care intervention (professional oral care from a dentist three times a week for 1 year)
Study: 19892414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no oral care intervention)
Study: 12391509
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate (220 micro g/puff) at 2 puffs twice daily for 3 months
Study: 9927363
Drug: CT (Conservative
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT (Conservative Treatment)
Study: 21153417
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg/day 3 hours before racing
Study: 11777296
Drug: Selective α1-blockers
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selective α1-blockers
Study: 11777296
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo or active treatment arms)
Study: 7951680
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral physostigmine plus clonidine
Study: 7951680
Drug: Oral physostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral physostigmine alone
Study: 3295935
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of clonidine
Study: 29249618
Drug: Guided imagery
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided imagery combined with relaxation therapy and other complementary therapies (e.g., hand and foot 'M' technique, education on pain management, relaxation exercises, respiration exercises, meditation, soothing music, nature sounds)
Study: 29100709
Drug: Influenza vaccine
Normalized name: Influenza vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccine (Cohort 2)
Study: 25660434
Drug: Duloxetine 60-120
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60-120 mg/d
Study: 12959269
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg every 12 h
Study: 12959269
Drug: Nicardipine 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 50 mg every 12 h
Study: 12959269
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of metoprolol and nicardipine
Study: 2888152
Drug: Quazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quazepam (15 or 30 mg)
Study: 2888152
Drug: Triazolam (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.5 or 1.0 mg)
Study: 17322150
Drug: golimumab (0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: golimumab (0.1, 0.3, 1, 3, 6, or 10 mg/kg)
Study: 15564757
Drug: Topical brinzolamide
Normalized name: Brinzolamide
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical brinzolamide
Study: 7603218
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin supplement (1 mg vitamin B12, 1.1 mg folate, 5 mg vitamin B6)
Study: 7603218
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin supplement
Study: 2665884
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (50 mg i.m. every 3 weeks)
Study: 391427
Drug: Fixed alternate
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed alternate treatment program involving Adriamycin and L‐PAM and Cytoxan, 5‐Fluorouracil, and Prednisone
Study: 391427
Drug: Fixed alternate
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed alternate treatment program
Study: 391427
Drug: Induction treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction treatment programs (Adriamycin and L‐PAM versus Cytoxan, 5‐Fluorouracil, and Prednisone)
Study: 391427
Drug: Fixed alternating
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed alternating treatment group
Study: 31994720
Drug: Intravenous ET-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ET-1 infusion (8 ng/kg/min for 20 minutes)
Study: 26082203
Drug: Dexamethasone 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 1.25 mg
Study: 19301940
Drug: Klarithran MR
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klarithran MR (generic formulation of clarithromycin)
Study: 19301940
Drug: Klacid XL
Normalized name: XL-888
DrugBank: XL-888 (DB12981)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klacid XL (originator formulation of clarithromycin)
Study: 17709915
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg daily for 3 months
Study: 17709915
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg daily for 3 months
Study: 9663813
Drug: Dihydrocodeine 60
Normalized name: dihydrocodeine bitartrate 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydrocodeine 60 mg with quinidine 50 mg
Study: 2595270
Drug: Citrate (46
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrate (46 mmol/l) in effervescent glucose-electrolyte solution
Study: 2595270
Drug: Betaine (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (36 mmol/l) in effervescent glucose-electrolyte solution
Study: 3003317
Drug: Bicarbonate-containing oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicarbonate-containing oral rehydration solution
Study: 29241890
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (chemotherapy for all)
Study: 22105586
Drug: Oseltamivir (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir (75 mg)
Study: 11453509
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) nasal spray, 42 micrograms/spray, administered intranasally twice daily for two weeks.
Study: 11453509
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal spray (placebo), administered intranasally twice daily for two weeks.
Study: 1552095
Drug: Quinidine (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine (1,500 mg/day for days 1-3, then 1,500 mg + verapamil 240 mg/day for days 4-6)
Study: 7846938
Drug: Quinidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine and verapamil (1,500 mg + 240 mg/day)
Study: 1552095
Drug: Amiodarone (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiodarone (1,200 mg/day intravenously for days 1-3, then 800 mg/day orally for days 4-14)
Study: 7846938
Drug: Quinidine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine and verapamil (480 mg/day + 240 mg/day)
Study: 3276824
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (CAFVP followed by surgery or RT)
Study: 31564697
Drug: Serum MMP‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum MMP‐9 levels in patients with PSD (658.8 ng/mL)
Study: 30055336
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment delivered by peer coaches over 18 months
Study: 30055336
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss treatment delivered by peer coaches
Study: 24852376
Drug: Nitazoxanide 600
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 600 mg twice daily for 5 days
Study: 24852376
Drug: Nitazoxanide 300
Normalized name: Nitazoxanide
DrugBank: Nitazoxanide (DB00507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitazoxanide 300 mg twice daily for 5 days
Study: 19682359
Drug: Rapid reduction
Normalized name: MEADOWFOAM SEED OIL 4 mg in 100 g / CHRYSANTHELLUM INDICUM FLOWER 3 mg in 100 g / MENTHA ARVENSIS FLOWER OIL 2 mg in 100 g / SACCHARUM OFFICINARUM WHOLE 2 mg in 100 g / ROSMARINUS OFFICINALIS FLOWER 2 mg in 100 g / JOJOBA OIL 4 mg in 100 g / CENTELLA ASIATICA ROOT 2 mg in 100 g / AGAVE TEQUILANA LEAF 5 mg in 100 g / HAMAMELIS VIRGINIANA TOP WATER 4 mg in 100 g TOPICAL CREAM [MELAO Rapid Reduction Eye Cream]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid reduction with nicotine patches and acute nicotine replacement therapy
Study: 19682359
Drug: Standard abrupt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard abrupt cessation with nicotine patches only
Study: 17633358
Drug: Conventional and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional and symptomatic treatment (Control)
Study: 14999518
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug plus intranasal calcitonin (group 2)
Study: 14999518
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug (group 1)
Study: 14999518
Drug: Antithyroid drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid drug (group 1) and Antithyroid drug plus intranasal calcitonin (group 2)